can glp 1 cause heart issues How GLP-1 Medications Reduce Disease Risk GLP-1 Agonists in Cardiovascular Diseases:

The Australia GLP-1 receptor agonist market size was valued at USD 570.49 million in 2025 and is expected to hit around USD 2,117.46 million by 2035, growing at a CAGR of 14.01% from 2026 to 2035.

Key Ingredients & Benefits: Berberine HCl (1500 mg) Supports blood sugar regulation and enhances insulin sensitivity

The hype hasn't erased the very real worries people have about long-term use, side effects, and the financial toll

At the same time, ultra-long-acting injectables are emerging as another theme of innovation

Noom has launched Proactive Health Microdose GLP-1 Rx, positioning the program as a preventive health offering rather than a weight loss solution

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatments